

Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting
Shelter #1 Sunday Park Brandermill
4602 Millridge Parkway
Midlothian, Va. 23112
Phone Number 1-866-692-4530
Access code: 2423 967 0500

Monday, September 27, 2021 - 1:00 p.m.

Welcome and Comments from DMAS' Director

Chethan Bachireddy, MD, CMO, Chair

Call to Order

Chethan Bachireddy, MD, CMO, Chair

Approval of Minutes from March 18, 2021, Meeting

P&T Committee Members

**Confidential Meeting (Pricing Information Discussion)
With Lunch**

P&T Committee Members & DMAS Staff

Phase II – New Drug Review (Therapeutic Class)

Brand Drugs

- Kloxxado[®] Spray (Nasal) *(Opiate Dependence Treatments)*
- Plegridy[®] (IM) & Ponvory[™] (Oral) *(Multiple Sclerosis Agents)*
- Qelbree[®] (Oral) *(Stimulants and Related Agents)*

Generics Drugs and New Dosage Forms –

- Tazarotene generic for Fabior[®] *(Acne Agents, Topical)*
- Skyrizi[™] Pen new dosage form *(Cytokine and Cam Antagonists)*
- Clobetex[®] Kit new dosage form *(Steroids, Topical Very High)*

PDL Phase I – Annual Review -Therapeutic Classes with Updates

Antibiotics/Anti-Infectives

- Antibiotics, Vaginal

Antivirals

- HIV *(Potential new PDL class and new Closed Class)*

Blood Modifiers

- Bile Salts

Cardiac Medications

- Angiotensin Modulators II *(includes Direct Renin Inhibitors & combination products)*
- Lipotropics, Statins
- Lipotropics, Other (includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibrin Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents)
- Pulmonary Arterial Hypertension Agents, Oral/Inhaled/Injectable *(includes Endothelin-1 agents, PDE-5 Inhibitors, Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators)*

Central Nervous System

- Anticonvulsants *(Potential new Closed class)*
- Movement Disorder Agents *(Potential new PDL class and new Closed Class)*

Dermatitis

- Immunomodulators, Atopic Dermatitis (*Potential new PDL class and new Closed Class*)

Endocrine & Metabolic Agents

- Hereditary Angioedema (HAE)

Genitourinary

- Bladder Relaxants

Ophthalmic

- Allergic Conjunctivitis (includes Ophthalmic Antihistamines & Mast Cell Stabilizers)
- Antibiotics
- Anti-inflammatory/ immunomodulators (*Potential new PDL class and new Closed Class*)

Respiratory

- Bronchodilators, Long-Acting Beta Adrenergics
- Glucocorticoids (*includes nebulized solutions, metered dose inhalers and combinations*) (*Closed Class*)
- Intranasal Rhinitis (includes Antihistamines and Corticosteroids)

PDL Phase I – Annual Review

Therapeutic Classes without Significant Updates (reviewed by the Department)

Antivirals

- Hepatitis C

Blood Modifiers

- Phosphate Binders

Cardiac Medications

- Angiotensin Modulators (includes ACEs, ARBs, & CCB combination products)
- Antihypertensives, Sympatholytics (Closed Class)
- Beta Blockers (includes combination products)
- Calcium Channel Blockers (includes dihydropyridine and non-dihydropyridine agents)

Central Nervous System

- Alzheimer's Agents
- Antipsychotics (includes oral and long acting injectables) This class will be reviewed in the Spring.
- Antidepressants, SSRI
- Antidepressants, Other
- Sedative Hypnotics

Dermatitis

- Steroids, Topical

Endocrine & Metabolic Agents

- Growth Hormones (*Closed Class*)
- Progestins for Cachexia

Gastrointestinal

- Antiemetic/Antivertigo Agents
- GI Motility, Chronic
- H. pylori Agents
- Histamine-2 Receptor Antagonists (H-2RA)
- Proton Pump Inhibitors
- Ulcerative Colitis

Genitourinary

- BPH Agents (includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitors for BPH treatment)

Ophthalmic

- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (includes Ophthalmic NSAIDS & Corticosteroids)
- Glaucoma

Respiratory

- Anti-Allergens
- Antibiotics, Inhaled (*Closed Class*)
- Antihistamines Minimally Sedating
- Bronchodilators, Short Acting Beta Adrenergics
- COPD (*includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors*) (*Closed Class*)
- Cough & Cold Agents (*Legend*)
- Epinephrine, Self-Injected
- Leukotriene Modifiers

Final determination of changes of preferred/Nonpreferred

P&T Committee Members & DMAS Staff

Criteria discussion for Preferred drugs

Next Meeting – March 17, 2022 (tentative)

Chair